tbuckley/cabot-search huggingface dataset:
Medical Identity Theft: A Case Report
Authors: Akshit Sharma, Paramdeep Baweja
Journal: Annals of Internal Medicine (2017)

Letters7 March 2017Medical Identity Theft: A Case ReportAkshit Sharma, MD and Paramdeep Baweja, MDAkshit Sharma, MDFrom University of Missouri–Kansas City School of Medicine, Kansas City, Missouri.Search for more papers by this author and Paramdeep Baweja, MDFrom University of Missouri–Kansas City School of Medicine, Kansas City, Missouri.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0360 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Medical identity theft takes place when a person uses someone else's health insurance or medical information to obtain treatment (1). According to the Federal Trade Commission, 8.3 million persons were victims of identity theft in the United States in 2005 (2) and cases of medical identity theft have increased in recent years (1).Purpose: To alert clinicians to the problem of medical identity theft.Case Report: A 40-year-old man presented to our cardiology clinic to establish care regarding his prosthetic aortic valve. His medical history included rheumatic heart disease with severe regurgitation from the valve, which had been replaced ...References1. Ponemon Institute. Fifth annual study on medical identity theft. February 2015. Accessed at http://medidfraud.org/wp-content/uploads/2015/02/2014_Medical_ID_Theft_Study1.pdf on 25 January 2017. Google Scholar2. Conde C. Flagging identity theft: is the patient who he says he is? Tex Med. 2009;105:43-6. [PMID: 19582648] MedlineGoogle Scholar3. Davis N, Lemery C, Roberts K. Identity theft and fraud—the impact on HIM operations. J AHIMA. 2005;76:64A-D. [PMID: 15871474] MedlineGoogle Scholar4. Mancini M. Medical identity theft in the emergency department: awareness is crucial. West J Emerg Med. 2014;15:899-901. [PMID: 25493150] doi:10.5811/westjem.2014.8.22438 CrossrefMedlineGoogle Scholar5. Wikipedia. Anthem Medical data breach. 2016. Accessed at http://wikipedia.org/wiki/Anthem_medical_data_breach on 26 January 2017. Google Scholar Author, Article, and Disclosure InformationAffiliations: From University of Missouri–Kansas City School of Medicine, Kansas City, Missouri.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0360. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe missing spleen – A diagnosis of medical identity fraud in surgery: Case reportDFP: A Data Fragment Protection Scheme for mHealth in Wireless Network 7 March 2017Volume 166, Issue 5Page: 380KeywordsAortic valveEchocardiographyExerciseHealth careHealth information technologyHealth insuranceStenosisSurgeonsSurgeryTheft ePublished: 7 March 2017 Issue Published: 7 March 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The microbiome in allergic disease: Current understanding and future opportunities—2017 PRACTALL document of the American Academy of Allergy, Asthma &amp; Immunology and the European Academy of Allergy and Clinical Immunology
Authors: Yvonne J. Huang, Benjamin J. Marsland, Supinda Bunyavanich, Liam O'Mahony, Donald Y.M. Leung, Antonella Muraro, Thomas A. Fleisher
Journal: Journal of Allergy and Clinical Immunology (2017)
Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study
Authors: Murielle Roussel, Valerie Lauwers-Cances, Nelly Robillard, Karim Belhadj, Thierry Facon, Laurent Garderet, Martine Escoffre, Brigitte Pegourie, Lotfi Benboubker, Denis Caillot, Cecile Fohrer, Philippe Moreau, Xavier Leleu, Herve Avet-Loiseau, Michel Attal
Journal: Blood (2016)
Prospective Evaluation of MRD-Kinetics in 274 Children with High-Risk ALL Treated in Trial ALL-BFM 2000: Insights into Development of Resistance and Impact on Further Refinement of Treatment Stratification Strategies.
Authors: André Schrauder, Martin Stanulla, Thomas Flohr, Gunnar Cario, Rolf Köhler, Renate Panzer-Grümayer, Beat Schäfer, Martin Zimmermann, Christina Peters, Claus R. Bartram, Martin Schrappe
Journal: Blood (2007)
Allogeneic Hematopoietic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High Risk Multiple Myeloma: Comparative Analysis of Outcomes Between Unrelated and Related Donor
Authors: Jean El-Cheikh, Sabine Furst, Anne Marie Stoppa, Roberto Crocchiolo, Catherine Faucher, Luca Castagna, Angela Granata, Claire Oudin, Patrick Ladaique, Boris Calmels, Claude Lemarie, jean Marc schiano De Colella, Christian Chabannon, Didier Blaise
Journal: Blood (2011)
MicroRNA 181b‐3p and its target importin α5 regulate toll‐like receptor 4 signaling in Kupffer cells and liver injury in mice in response to ethanol
Authors: Paramananda Saikia, Damien Bellos, Megan R. McMullen, Katherine A. Pollard, Carol de la Motte, Laura E. Nagy
Journal: Hepatology (2017)

Increased inflammatory signaling by Kupffer cells contributes to alcoholic liver disease (ALD). Here we investigated the impact of small, specific-sized hyaluronic acid of 35 kD (HA35) on ethanol-induced sensitization of Kupffer cells, as well as ethanol-induced liver injury in mice. Unbiased analysis of microRNA (miRNA) expression in Kupffer cells identified miRNAs regulated by both ethanol and HA35. Toll-like receptor 4 (TLR4)-mediated signaling was assessed in primary cultures of Kupffer cells from ethanol- and pair-fed rats after treatment with HA35. Female C57BL6/J mice were fed ethanol or pair-fed control diets and treated or not with HA35. TLR4 signaling was increased in Kupffer cells by ethanol; this sensitization was normalized by ex vivo treatment with HA35. Next generation sequencing of Kupffer cell miRNA identified miRNA 181b-3p (miR181b-3p) as sensitive to both ethanol and HA35. Importin α5, a protein involved in p65 translocation to the nucleus, was identified as a target of miR181b-3p; importin α5 protein was increased in Kupffer cells from ethanol-fed rats, but decreased by HA35 treatment. Overexpression of miR181b-3p decreased importin α5 expression and normalized lipopolysaccharide-stimulated tumor necrosis factor α expression in Kupffer cells from ethanol-fed rats. In a mouse model of ALD, ethanol feeding decreased miR181b-3p in liver and increased expression of importin α5 in nonparenchymal cells. Treatment with HA35 normalized these changes and also protected mice from ethanol-induced liver and intestinal injury.miR181b-3p is dynamically regulated in Kupffer cells and mouse liver in response to ethanol and treatment with HA35. miR181b-3p modulates expression of importin α5 and sensitivity of TLR4-mediated signaling. This study identifies a miR181b-3p-importin α5 axis in regulating inflammatory signaling pathways in hepatic macrophages. (Hepatology 2017;66:602-615).
Prevention of Alloimmune Platelet (Plt) Refractoriness In a Dog Model Requires Both Removal and Inactivation of Contaminating Donor White Blood Cells (WBCs)
Authors: Sherrill J. Slichter, Esther Pellham, S. Lawrence Bailey, Todd Christoffel, Lakshmi Gaur, Yvette Latchman, Karen Nelson, Doug Bolgiano
Journal: Blood (2010)
High-Flow Oxygen vs Noninvasive Ventilation for Postextubation Respiratory Failure—Reply
Authors: Gonzalo Hernández, Laura Colinas, Alfonso Canabal
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry
Authors: Brigitte Dupriez, Sylvie Chevret, Jean-Christophe Ianotto, Francoise Boyer, Pascale Cony-Makhoul, Gabriel Etienne, Mathieu Wemeau, Jérome Rey, Laurent Knoops, Jean-Loup Demory, Eric Lippert, Francois Girodon, Laurence Legros, Anne Vekhoff, Stephane Courby, Fabienne Vacheret, Nathalie Cambier, Stephane Giraudier, Suzanne Tavitian, Kamel Laribi, Sandra Malak, Dana Ranta, Fiorenza Barraco, Isabelle Plantier, Sophie Dupire, Marc Simon, Selim Corm, Ahmad AL Jijakli, Philippe Rodon, Lise Willems, Bohrane Slama, Ronan Le Calloch, Pierre Morel, Valerie Ugo, Jean-Jacques Kiladjian
Journal: Blood (2016)
Smoking History and Pre-Transplant Pulmonary Function Predict Post-Transplant Respiratory Failure, Acute Renal Failure Requiring Dialysis and 100-Day Mortality in Allogeneic Bone Marrow Transplantation
Authors: Lekha Mikkilineni, Kinjal Parikh, Fern Martin, Dolores Grosso, Benjamin Leiby, Onder Alpdogan, Matthew Carabasi, Margaret Kasner, Thomas R. Klumpp, Ubaldo Martinez-Outschoorn, Manish Sharma, Mark Weiss, John L. Wagner, Neal Flomenberg, Joanne E. Filicko-O'Hara
Journal: Blood (2015)
Febrile Neutropenia Outcome in Hemato-Oncological Patients after the Implementation of an Adapted Therapeutic Protocol at a University Hospital in Uruguay
Authors: Sofia Grille, Boada Matilde, Regina Guadagna, Maria Noel Spangenber, Felipe Lemos, Mariana Stevenazzi, Lilian Diaz, Cecilia Guillermo
Journal: Blood (2015)
Abstract P3-06-08: HDAC6 deacetylates HMGN2 to regulate Stat5a activity and breast cancer growth
Authors: CV Clevenger, JM Craig, AA Fiorillo, YB Feeney, JC Harrell, TR Medler
Journal: Cancer Research (2017)

Abstract Stat5 is a transcription factor utilized by several cytokine/hormone receptor signaling pathways that promotes transcription of genes associated with proliferation, differentiation, and survival of cancer cells. However, there are currently no clinically approved therapies that target Stat5, despite ample evidence that it contributes to breast cancer pathogenesis. Previous research in our lab has shown that the high mobility group nucleosome binding domain 2 (HGMN2) protein serves as a Stat5 co-activator. The activity of HMGN2 has been previously shown to be regulated by acetylation. Here, we show that deacetylation of HMGN2 on lysine residue K2 by histone deacetylase 6 (HDAC6) promotes Stat5-mediated transcription and breast cancer growth. Conversely, in vitro HDAC6 inhibition by pharmacologic and knock-down approaches enhanced HMGN2 acetylation with a concomitant reduction of in vitro Stat5-mediated signaling and global gene expression, and breast cancer growth. In vitro and in vivo treatment of traditional and patient-derived xenograft models with HDAC6 inhibitors resulted in a highly significant reduction of tumor growth. Translationally, it was also found that high levels of acetylated K2 were present in normal human breast tissue, which was lost in primary breast cancers and lymph node metastases. This suggests that blockade of HMGN2 deacetylation as described above is a novel treatment for breast cancer, given that existing HDAC6 inhibitors have a favorable toxicity profile in Phase I trials of other tumor types. Altogether, these results reveal a novel mechanism through which HDAC6 regulates the transcription of Stat5 target genes and demonstrates the utility of HDAC6 inhibition as a potential breast cancer therapeutic. Citation Format: Clevenger CV, Craig JM, Fiorillo AA, Feeney YB, Harrell JC, Medler TR. HDAC6 deacetylates HMGN2 to regulate Stat5a activity and breast cancer growth [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-06-08.
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
Authors: Hervé Avet-Loiseau, Tineke Casneuf, Christopher Chiu, Jacob P. Laubach, Je-Jung Lee, Philippe Moreau, Torben Plesner, Hareth Nahi, Nushmia Z Khokhar, Ming Qi, Jordan Schecter, Victoria Carlton, Xiang Qin, Kevin Liu, Kaida Wu, Sen H. Zhuang, Tahamtan Ahmadi, A. Kate Sasser, Jesús San-Miguel
Journal: Blood (2016)
Generation of a Live Attenuated Influenza Vaccine that Elicits Broad Protection in Mice and Ferrets
Authors: Lulan Wang, Su-Yang Liu, Hsiang-Wen Chen, Juan Xu, Maxime Chapon, Tao Zhang, Fan Zhou, Yao E. Wang, Natalie Quanquin, Guiqin Wang, Xiaoli Tian, Zhanlong He, Longding Liu, Wenhai Yu, David Jesse Sanchez, Yuying Liang, Taijiao Jiang, Robert Modlin, Barry R. Bloom, Qihan Li, Jane C. Deng, Paul Zhou, F. Xiao-Feng Qin, Genhong Cheng
Journal: Cell Host & Microbe (2017)
Improving QOL and safety while reducing costs: Evidence-based adjuvant chemotherapy of colorectal cancer (CRC).
Authors: William S. Shimp, Akhil Kumar, Laura Rose Bobolts, James Edward Krook, Val Fishman, Sharon Davis, Carol Anthony, Robert Walton, Dinah Huff, Marc L. Fishman, William J. Hrushesky
Journal: Journal of Clinical Oncology (2013)

e14646 Background: The addition of oxaliplatin in adjuvant chemotherapy for stage II CRC and for elderly (≥ 70) patients with stage II or III CRC requires careful consideration. Most patients with stage II or III CRC receive oxaliplatin-based adjuvant regimens (Abrams. J Clin Oncol 2011). Mature results of the adjuvant MOSAIC and C-07 trials, however, failed to show improvement in OS or DFS among the elderly (≥ 70 years) and those with stage II CRC (Tournigand. J Clin Oncol 2012). Oxaliplatin causes neuropathy, increases the incidence and severity of febrile neutropenia, and adds substantial cost for both oxaliplatin and WBC growth factors. Methods: All chemotherapy requests submitted to Oncology Analytics for stage II and III CRC from 2009 through 2012 were analyzed. Utilization of oxaliplatin was retrospectively analyzed, with special attention to its use in those who were elderly (≥ 70 years), and for those of any age with stage II. Results: Our review showed a total of 242 adjuvant chemotherapy requests in stage II/III CRC. The majority of them, 57% (138/242), were elderly (≥ 70 years) with Stage II/III, and 24% (58/242) of any age had stage II. Thirty-four (14%) were both elderly and stage II. Overall, more than two thirds, 71% (171/242), received oxaliplatin containing regimens. More than two thirds of the elderly, regardless of stage, and more than half of all stage II patients, regardless of age, were treated with oxaliplatin containing regimens. Conclusions: The historical predominance of oxaliplatin use in the adjuvant setting, among patients over seventy years of age and/or those with stage II CRC, needs to be addressed as a priority. With mature data from the MOSAIC and C-07 trials, oncologists need to change prescribing behavior to provide less toxic therapies, thereby diminishing the incidence of neuropathy and reducing the risk of febrile neutropenia. The elimination of oxaliplatin in these subsets will also diminish costs for the Medicare population by a quarter billion dollars each year, without an adverse impact on outcome. [Table: see text]
Cholesteryl Ester Crystals in Lysosomal Acid Lipase Deficiency
Authors: Vladimir Ivashkin, Maria Zharkova
Journal: New England Journal of Medicine (2017)

An 18-year-old woman had elevated aminotransferase levels and a workup negative for infectious and autoimmune disease. Liver biopsy revealed birefringent cholesteryl ester crystals consistent with lysosomal acid lipase deficiency.
Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.
Authors: Karl J. Aichberger, Matthias Mayerhofer, Maria-Theresa Krauth, Hans Skvara, Stefan Florian, Karoline Sonneck, Cahit Akgul, Sophia Derdak, Winfried F. Pickl, Volker Wacheck, Edgar Selzer, Brett P. Monia, Richard Moriggl, Peter Valent, Christian Sillaber
Journal: Blood (2004)
Abstract A41: Biomechanics: A new therapeutic innovation deposit – From the proof of concept to the proof of efficacy
Authors: Remy Brossel
Journal: Cancer Research (2017)

Abstract Malignant tissue can be normalized in vitro using mechanical signals. A biomechanical treatment has been applied to a tumor of human origin grafted subcutaneously in mice and demonstrated the normalizing effect of stress on tumor growth in vivo. Following this Proof of Concept, a feasibility study has been performed to build a prototype for a Proof of Efficacy: Application of a Constraint Field on human pancreatic cancer grafted in the pancreas of mice. Two devices are combined to generate the local constraint: First a generator of Gradient of Magnetic Field (GMF), second magnetizable iron nanoparticles located in the neovessels surrounding the tumor itself. Nanoparticles act as bioactuators transforming magnetic energy in mechanical energy. This feasibility study was performed on the GMF generator with two opposite permanent magnets. The pressure (Pa) created on the neovessels is: P = Fv.L.Ms,v.dB/dx L is the stroma thickness (m); Fv is the nanoparticle volume proportion of stroma; Ms,v is the magnetization of nanoparticles (A/m); dB/dx is the magnetic induction gradient in stroma thickness direction (T/m). Iron-core coils are the best means to obtain our goal: A magnetic pressure of about 100 to 500 Pa on the tumor surface. The tumor is a one-centimeter-diameter sphere located at the center of our measured zone, a tube with 3 cm square section. Three dimensional magnetic simulations with a finite element method show that a magnetic induction gradient of 50 T/m is achievable. This gradient can be maintained permanently, can vary with time, and can have a variable direction in the field of study. The other variables that increase pressure are: The proportion of iron particles (greater than 100 mg/ml), the thickness of stroma, and the magnetization of particles. The experimental laboratory environment in which the anesthetized rodents are studied must permit heat dissipation to obtain reproducible results with no influence of temperature. The power losses do not exceed 600 watts, so the use of air-cooling is adequate. The magnetic induction gradients are strong, but obtainable at the tumor-stroma interface. The progression to a whole human prototype will necessarily require supra-conductor coils. We will present the data on changes in in vivo human tumor size and configuration with the application of external quantifiable constraint field in the experimental mouse. Citation Format: Remy Brossel. Biomechanics: A new therapeutic innovation deposit – From the proof of concept to the proof of efficacy. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr A41.
Abstract P5-09-03: Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients
Authors: FJ Couch, J Lilyquist, J Na, C Hu, EC Polley, H Shimelis, M Akinhanmi, R McFarland, H LaDuca, DE Goldgar, JS Dolinsky
Journal: Cancer Research (2017)

Abstract Clinical genetic testing of individuals with a personal or family history of breast and ovarian cancer using panels for BRCA1/2 and other candidate cancer predisposition genes has become routine clinical practice. Several of the genes on hereditary cancer testing panels have been strongly associated with specific subtypes of breast cancer. In particular, individuals with germline mutations in BRCA1 predominantly develop estrogen receptor (ER)-negative and triple negative (TN) (estrogen receptor negative, progesterone receptor negative, HER2 negative) breast tumors. In contrast, CHEK2 and ATM mutations have been associated with ER-positive breast cancer. In this study, associations between mutations in panel genes and breast cancer subtypes were evaluated. A cohort of 60,000 breast cancer patients tested for germline cancer predisposing mutations using hereditary cancer gene panels was utilized. Information on personal and family cancer history, age of diagnosis, tumor pathology, and ethnicity of patients was obtained from test requisition forms or by follow up with ordering health care providers. Mutations in each gene were combined into four histological subtypes (triple negative; HER2 positive; ER-positive,HER2-positive; and ER-positive,HER2 negative). Associations for each subtype were estimated by case-control analyses comparing the frequencies of pathogenic mutations in each subtype with frequencies from non-TCGA controls from the Exome Aggregation Consortium (ExAC) database. In addition, case-case analyses were conducted to assess enrichment of gene mutations in specific breast cancer subtypes. Among the observed associations between genes and breast cancer subtypes, mutations in CHEK2 and ATM were highly enriched in luminal breast cancers and BARD1 was specifically associated with TN breast cancer. Refining the spectrum of pathological correlates with mutations in hereditary breast cancer genes will aid gene specific cancer risk management, and may accelerate the development of novel gene-specific therapeutic interventions. Citation Format: Couch FJ, Lilyquist J, Na J, Hu C, Polley EC, Shimelis H, Akinhanmi M, McFarland R, LaDuca H, Goldgar DE, Dolinsky JS. Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-09-03.
Validation of needle-based confocal laser endomicroscopy
Authors: Lizzy Wijmans, Jouke Annema
Journal: Endoscopy (2017)

We congratulate Benias et al. for their work on needle-based confocal laser endomicroscopy (nCLE) for the evaluation of malignant lymph nodes [1]. Confocal laser endomicroscopy is a laser-based optical technique that enables real-time visualization of tissue on a microscopic level. In combination with endoscopic ultrasound (EUS), the nCLE technique can possibly be helpful in identifying the optimal sampling location or even evolve to a real “optical biopsy” tool in the diagnosis and staging of pancreatic [2] and lung cancer [3].
Central Nervous System Relapses in Patients with Diffuse Large B Cell Lymphoma: Multicenter Retrospective Analysis in Korea
Authors: Seok Jin Kim, Gyeong- Won Lee, Byung Soo Kim, Sung Yong Oh, Ho-Jin Shin, Hee Sook Park, Jin Seok Kim, Hawk Kim, Deok-Hwan Yang, Jinny Park, Won Seog Kim, Cheolwon Suh
Journal: Blood (2008)
Mitoxantrone and Etoposide with or without Intermediate-Dose Cytarabine for the Treatment of Patients with Primary Induction Failure or Relapsed Acute Myeloid Leukemia
Authors: Steven Trifilio, Alfred Radamaker, Diane Newman, Kathryn Coyle, Katrin Carlson Leuer, Jayesh Mehta, Jessica Kaplan Altman, Olga Frankfurt, Martin S. Tallman
Journal: Blood (2010)